RB1 mutations were found to be prone to high-grade bladder cancer (23), astrocytic gliomas (24), and Merkel cell carcinoma (25), and they could function by activating the NF-κB pathway and exerting anti-inflammatory effects (26). Here, RB1 is linked to urinary bladder carcinoma.